Clinical Trial Update: ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating gefitinib (ZD1839) with hypofractionated radiotherapy and immobilization for advanced non-small cell lung cancer; the study is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• gefitinib (ZD1839) (gefitinib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Non-Small Cell Lung Carcinoma (NSCLC) | Phase 1 | Status: COMPLETED | Results posted: 2014-08-11